Scinopharm Taiwan, Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 05, 2020 at 08:09 pm
Share
ScinoPharm Taiwan, Ltd. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was TWD 758.327 million compared to TWD 683.613 million a year ago. Operating income was TWD 101.975 million compared to TWD 30.766 million a year ago. Net income was TWD 76.446 million compared to TWD 32.209 million a year ago. Basic earnings per share was TWD 0.1 compared to TWD 0.04 a year ago. For the nine months, sales was TWD 2,208.930 million compared to TWD 2,073.231 million a year ago. Operating income was TWD 354.400 million compared to TWD 209.786 million a year ago. Net income was TWD 273.901 million compared to TWD 167.809 million a year ago. Basic earnings per share was TWD 0.35 compared to TWD 0.21 a year ago.
ScinoPharm Taiwan Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of active pharmaceutical ingredients. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The Company is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The Company operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
SCINOPHARM TAIWAN, LTD. 
